Sugi Predict

Sugi Predict / Compounds / SCHEMBL507079

SCHEMBL507079

SCHEMBL507079

Cc1cccc(C(C)O)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CCR1 P32246 1/20 0.46
▸ CCR8 P51685 1/20 0.46
▸ IRAK4 Q9NWZ3 2/20 0.46
▸ HTT P42858 1/20 0.46
▸ RECQL P46063 1/20 0.46
▸ NOS3 P29474 1/20 0.43
▸ NOS2 P35228 1/20 0.43
▸ RAB9A P51151 3/20 0.39
▸ MEN1 O00255 3/20 0.39
▸ KMT2A Q03164 3/20 0.39
▸ FDPS P14324 1/20 0.38
▸ FDFT1 P37268 1/20 0.38
▸ P2RX7 Q99572 1/20 0.37
▸ MAP4K4 O95819 1/20 0.37
▸ METAP2 P50579 1/20 0.36
▸ HSD11B1 P28845 3/20 0.35
▸ GRM5 P41594 3/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35
▸ ALDH1A1 P00352 3/20 0.34
▸ KDM4E B2RXH2 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL507316 1.00 CCR1 (0.46) CCR1CCR8IRAK4HTTRECQL
SCHEMBL24375835 1.00 CCR1 (0.46) CCR1CCR8IRAK4HTTRECQL
SCHEMBL29860803 0.85 PGK1 (0.41) IRAK4MEN1KMT2AHSD11B1TDP1
SCHEMBL4273303 0.85 PGK1 (0.41) IRAK4MEN1KMT2AHSD11B1TDP1
SCHEMBL14577729 0.84 CCR1 (0.48) CCR1CCR8HTTRECQLNOS3
SCHEMBL24925771 0.83 HTT (0.43) CCR1CCR8IRAK4HTTRECQL
SCHEMBL102150 0.81 CCR1 (0.50) CCR1CCR8HTTRECQLNOS3
SCHEMBL13915474 0.81 HTT (0.42) CCR1CCR8HTTRECQLNOS3
SCHEMBL19151578 0.80 NOS3 (0.46) CCR1CCR8HTTRECQLNOS3
SCHEMBL22849767 0.80 HTT (0.49) CCR1CCR8HTTRECQLNOS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024222860-A1 SALT OF MORPHOLINE HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF 江苏豪森药业集团有限公司 2024-10-31 — — WO disclosed
CN-118852146-A Crystal form of morpholine heterocyclic compound, and preparation method and application thereof 江苏豪森药业集团有限公司 2024-10-29 — — CN disclosed
CN-118176185-A 2- (Aryl-2-yl) morpholine and deuterated derivative thereof, preparation method and application 上海翰森生物医药科技有限公司 2024-06-11 — — CN disclosed
US-20240174683-A1 MAP4K1 INHIBITORS BAYER AKTIENGESELLSCHAFT (DE) 2024-05-30 — — US disclosed
EP-4310089-A1 NITROGEN-CONTAINING HETEROCYCLIC POLYCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF Shanghai Hansoh Biomedical Co., Ltd. (CN) 2024-01-24 — — EP disclosed
EP-4288437-A1 MAP4K1 INHIBITORS Bayer Aktiengesellschaft (DE) 2023-12-13 — — EP disclosed
WO-2023078392-A1 2-(ARYL-2-YL) MORPHOLINE AND DEUTERATED DERIVATIVE THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 上海翰森生物医药科技有限公司 2023-05-11 — — WO disclosed
WO-2022167627-A1 MAP4K1 INHIBITORS BAYER AKTIENGESELLSCHAFT (DE) 2022-08-11 — — WO disclosed
EP-3042900-B1 NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF FUJIFILM CORP (JP) 2020-09-23 — — EP disclosed
US-10273237-B2 Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN-α responses BRISTOL-MYERS SQUIBB COMPANY (US) 2019-04-30 — — US disclosed
CN-1681810-A Novel oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors PFIZER PROD INC (US) 2005-10-12 — — CN disclosed
WO-2005082859-A1 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS ELI LILLY AND COMPANY (US) 2005-09-09 — — WO disclosed
EP-1542994-A1 NOVEL TRIAZOLE AND OXAZOLE COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITOR Pfizer Products Inc. (US) 2005-06-22 — — EP disclosed
WO-2004078110-A2 FUSED IMIZADOLES AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS PFIZER PRODUCTS INC. (US) 2004-09-16 — — WO disclosed
US-20040176390-A1 Novel fused heteroaromatic compounds as transforming growth factor (TGF) inhibitors PFIZER INC 2004-09-09 — — US disclosed
US-20040110797-A1 Novel oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors PFIZER INC 2004-06-10 — — US disclosed
WO-2004026863-A1 NOVEL OXAZOLE AND THIAZOLE COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS PFIZER PRODUCTS INC. (US) 2004-04-01 — — WO disclosed
EP-1070052-A1 FUNGICIDE COMPOSITIONS COMPRISING A HYDROXIMIC OR HYDRAZONIC GROUP AVENTIS CROPSCIENCE S.A. (FR) 2001-01-24 — — EP disclosed
WO-1999051579-A1 FUNGICIDE COMPOSITIONS COMPRISING A HYDROXIMIC OR HYDRAZONIC GROUP AVENTIS CROPSCIENCE S.A. (FR) 1999-10-14 — — WO disclosed
US-4006127-A Cationic diazacyanine dyestuffs BAYER AKTIENGESELLSCHAFT (DT) 1977-02-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110797-A1 Novel oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors TGFBR1, TGFBR2, SMAD3 CCR1 637/4885CCR8 669/4885IRAK4 56/4885
US-20240174683-A1 MAP4K1 INHIBITORS MAP3K4, MAP4K4, MAP4K1 CCR1 1695/4885CCR8 3035/4885IRAK4 45/4885
US-10273237-B2 Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN-α responses TYK2, IFNG, IFNAR1 CCR1 1577/4885CCR8 911/4885IRAK4 22/4885
US-20040176390-A1 Novel fused heteroaromatic compounds as transforming growth factor (TGF) inhibitors SMAD3, TGFBR1, SMAD2 CCR1 1623/4885CCR8 1957/4885IRAK4 610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.